New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…
Recognized for its proprietary SELPAXT™ technology, Chromafora is setting a new standard for innovation and performance in advanced PFAS remediation.…
Manageable number of monthly hair restoration surgeries illustrates ISHRS members' hands-on, expert approach CHICAGO, June 10, 2025 /PRNewswire/ -- According to results…
June 09, 2025 08:00 ET | Source: PDS Biotechnology Corporation Event to Discuss the Changing Landscape of HNSCC in context…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…